List of Excipients in Branded Drug CLEOCIN HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CLEOCIN HYDROCHLORIDE	clindamycin hydrochloride	0009-0331	FD&C BLUE NO. 1
Pharmacia & Upjohn Company LLC	CLEOCIN HYDROCHLORIDE	clindamycin hydrochloride	0009-0331	FD&C YELLOW NO. 5
Pharmacia & Upjohn Company LLC	CLEOCIN HYDROCHLORIDE	clindamycin hydrochloride	0009-0331	GELATIN
Pharmacia & Upjohn Company LLC	CLEOCIN HYDROCHLORIDE	clindamycin hydrochloride	0009-0331	LACTOSE
Pharmacia & Upjohn Company LLC	CLEOCIN HYDROCHLORIDE	clindamycin hydrochloride	0009-0331	MAGNESIUM STEARATE
Pharmacia & Upjohn Company LLC	CLEOCIN HYDROCHLORIDE	clindamycin hydrochloride	0009-0331	STARCH, CORN

Cleocin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

Cleocin hydrochloride is the oral capsule form of clindamycin hydrochloride, an immediate-release lincosamide antibiotic. Its commercial opportunity is primarily in generic substitution, formulation differentiation, supply-chain efficiency, and lifecycle management rather than new chemical-entity exclusivity. The product has a mature active ingredient, established oral absorption, and a relatively simple capsule platform. The principal technical constraints are gastrointestinal tolerability, excipient compatibility, capsule stability, bioequivalence, and avoidance of unnecessary formulation changes that could complicate regulatory approval.

What is Cleocin hydrochloride?

Cleocin hydrochloride is an oral clindamycin product supplied as immediate-release capsules. Clindamycin is used for susceptible bacterial infections, including selected infections caused by anaerobic bacteria and gram-positive organisms. The hydrochloride salt is intended for oral administration; clindamycin phosphate is commonly used in injectable and topical products.

Attribute	Cleocin hydrochloride
Active ingredient	Clindamycin hydrochloride
Active moiety	Clindamycin
Dosage form	Immediate-release hard gelatin capsule
Common strengths	75 mg, 150 mg, and 300 mg clindamycin
Drug class	Lincosamide antibacterial
Administration	Oral
Regulatory pathway for generics	Abbreviated New Drug Application
Reference product	Cleocin HCl capsules
Biosimilar relevance	None
Primary commercial substitutes	Generic clindamycin hydrochloride capsules, clindamycin phosphate injection, topical clindamycin, and alternative antibiotics

The reference product’s clinical and regulatory profile is mature. Generic manufacturers therefore compete on cost, supply reliability, contract access, packaging, and selected excipient attributes rather than on novel pharmacology.

What excipients are used in Cleocin hydrochloride capsules?

The reference product and generic products use conventional capsule excipients. Published labeling identifies excipients such as lactose, corn starch, magnesium stearate, talc, and capsule-shell components, including gelatin and colorants. Exact composition can vary by strength, manufacturer, market, and labeling revision. Product-specific inactive-ingredient information is listed in FDA labeling and DailyMed records. [1,2]

A representative excipient architecture is:

Formulation function	Typical excipient category	Strategic purpose
Diluent	Lactose or other filler	Provides capsule fill volume and improves dose uniformity
Disintegrant	Corn starch or modified starch	Promotes capsule-content dispersion
Lubricant	Magnesium stearate	Reduces adhesion during blending and encapsulation
Glidant or processing aid	Talc or colloidal silicon dioxide	Improves powder flow
Capsule shell	Gelatin, water, titanium dioxide, iron oxides or approved colorants	Provides dosage-form integrity and identification
Optional stabilizing system	Selected pH modifiers or antioxidants, if justified	Supports stability in specific formulations

The principal excipient issue is not a complex delivery system. It is control of powder flow, blend uniformity, dissolution, moisture exposure, and capsule-machine performance.

Which excipient strategy is best for generic clindamycin hydrochloride?

The lowest-risk strategy is a conventional immediate-release formulation that closely matches the reference product’s performance without copying every inactive ingredient. The target should be rapid and consistent release, robust encapsulation, and a clean comparative dissolution profile.

Lactose-based formulation

Lactose is commercially attractive because it is inexpensive, widely available, and familiar to regulators. It can support good content uniformity when paired with an appropriate starch system.

Risks include:

• Labeling limitations for patients with lactose intolerance or rare galactose disorders.
• Potential supplier and grade variability.
• Moisture-related effects in some blends.
• Need to control particle size and bulk density.

Lactose remains suitable for a cost-focused generic unless the sponsor is targeting a lactose-free positioning.

Lactose-free formulation

A lactose-free product can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected starch-based systems. Such a formulation may support pharmacy and hospital procurement differentiation, particularly where excipient restrictions influence formulary decisions.

The commercial benefit is limited unless the product has a clear market-access strategy. Lactose-free status alone is unlikely to command a large premium in a mature antibiotic market. It may, however, improve eligibility for institutional tenders or specialty distribution channels.

Starch and superdisintegrant selection

Corn starch is a conventional choice for immediate-release capsule fill. Crospovidone, croscarmellose sodium, or sodium starch glycolate can improve disintegration, but a more aggressive disintegrant system is not automatically better. Excessive disintegrant loading can alter powder flow, increase blend segregation, or create dissolution behavior that differs from the reference product.

The preferred approach is a low-complexity formulation supported by comparative dissolution testing across physiologically relevant media.

Lubricant strategy

Magnesium stearate is standard for capsule manufacturing. Over-lubrication can reduce wetting and slow dissolution, particularly in low-solubility formulations or blends with hydrophobic excipient surfaces. The sponsor should control:

• Lubrication time.
• Magnesium stearate concentration.
• Specific surface area and grade.
• Blend shear.
• Dissolution after scale-up.

A formulation change that improves machine performance but slows release can create avoidable bioequivalence and product-quality risk.

What formulation patents protect Cleocin hydrochloride?

The original Cleocin hydrochloride formulation is a mature product, and the principal commercial barrier is unlikely to be an active formulation patent estate. The relevant intellectual-property analysis should distinguish among:

1. Original clindamycin composition and use patents.
2. Historical Cleocin product patents.
3. Later patents on modified-release, taste-masked, pediatric, topical, or combination products.
4. Manufacturing know-how and supplier controls.
5. Current Orange Book-listed patents, if any remain associated with the reference NDA.

Clindamycin hydrochloride capsules do not have the patent characteristics of a recently approved small-molecule product. The principal generic pathway is generally an ANDA referencing the listed drug, subject to the current Orange Book patent and exclusivity record. [3,4]

A sponsor should not assume that a patent covering topical clindamycin, clindamycin phosphate injection, a sustained-release system, or a different salt covers immediate-release Cleocin HCl capsules. Claim scope depends on the claims, listed dosage form, active ingredient, and approved use.

What is the Orange Book status of Cleocin hydrochloride?

The Orange Book is the controlling source for current listed-drug, patent, and exclusivity information. Historical Cleocin HCl capsule products are associated with clindamycin hydrochloride oral capsules and an original NDA record. The current commercial landscape consists largely of generic clindamycin hydrochloride capsules rather than a protected branded product with meaningful remaining market exclusivity. [3]

For an ANDA strategy, the sponsor should review:

• The active reference listed drug.
• NDA and product numbers.
• Current strengths and dosage forms.
• Listed patents and patent-use codes.
• Any unexpired exclusivity.
• Therapeutic-equivalence ratings of approved generic products.
• Reference standards and dissolution expectations.

Because Orange Book entries can change through patent-listing updates, delistings, and regulatory actions, commercial decisions should use the current FDA database rather than historical patent summaries.

When does Cleocin hydrochloride lose exclusivity?

Cleocin hydrochloride is a legacy small-molecule product. Its original regulatory and patent exclusivity periods expired long ago relative to the current generic market. No biosimilar exclusivity analysis applies because clindamycin is a chemically synthesized antibiotic, not a biologic.

The remaining commercial protections, if any, are more likely to arise from:

• Product-specific formulation patents.
• Manufacturing-process patents.
• Private-label or supply agreements.
• State or institutional purchasing arrangements.
• Temporary shortage conditions.
• Regulatory barriers to approval.
• Brand recognition and channel relationships.

The absence of meaningful original exclusivity does not eliminate launch risk. Generic entry depends on regulatory approval, manufacturing capacity, active pharmaceutical ingredient supply, wholesaler access, and price erosion.

Are Paragraph IV challenges relevant to Cleocin hydrochloride?

Paragraph IV litigation is generally a low-value issue for an old immediate-release clindamycin hydrochloride capsule unless an unexpired listed patent remains associated with the selected reference product. A sponsor should conduct a current Orange Book review before filing.

If no relevant unexpired patent is listed, the ANDA strategy may rely on a certification that does not require a Paragraph IV challenge. If a listed patent covers an approved use or formulation, the applicant must select the appropriate certification and assess whether the patent is relevant to the proposed label.

For this product class, litigation risk is more likely to arise from:

• Incorrect patent certification.
• Use of a protected indication.
• A later modified-release or specialty formulation.
• Trade dress or trademark disputes.
• Contractual disputes involving an authorized generic.

What FDA regulatory requirements apply to generic clindamycin hydrochloride?

An ANDA sponsor must establish pharmaceutical equivalence and bioequivalence to the reference listed drug. FDA’s product-specific guidance, where available, controls the recommended comparative approach. [5]

Core development requirements include:

• Same active ingredient and dosage form.
• Same strength as the reference product.
• Comparable inactive-ingredient safety profile.
• Comparative dissolution testing.
• In vivo bioequivalence when required.
• Demonstrated stability through the proposed shelf life.
• Container-closure compatibility.
• Microbiological quality controls.
• Manufacturing-process validation.
• Appropriate labeling for warnings, adverse reactions, and administration.

Clindamycin’s known association with antibiotic-associated diarrhea and Clostridioides difficile infection affects commercial positioning. A new excipient system cannot be marketed as reducing this risk without clinical evidence and appropriate regulatory authorization. [1,6]

What commercial opportunities exist for excipient reformulation?

1. Lactose-free generic capsules

A lactose-free product can target hospital systems, retail pharmacies, and prescribers seeking fewer excipient restrictions. The opportunity is strongest when the formulation preserves low cost and uses globally available materials.

2. Gluten-free and simplified excipient labeling

A short, transparent inactive-ingredient list can support institutional procurement and patient preference. Gluten-free claims require appropriate supplier qualification and contamination controls. The claim should be supported by manufacturing and testing documentation.

3. Vegetarian or non-gelatin capsules

Hydroxypropyl methylcellulose capsules can address vegetarian, religious, or animal-origin concerns. The change introduces different moisture behavior, shell mechanics, and dissolution characteristics. It should be evaluated as a formulation and packaging change, not treated as a cosmetic substitution.

4. Pediatric-friendly product formats

The oral capsule is poorly suited to young children and patients unable to swallow. Opportunities include an age-appropriate oral solution, suspension, sprinkle capsule, or dispersible dosage form. These products face greater development complexity because of taste, stability, dose flexibility, preservative selection, and bioequivalence strategy.

Clindamycin has a strong bitter taste profile. Taste masking can require polymer coatings, ion-exchange resins, lipid systems, or complex multiparticulates. These approaches may create new intellectual property but also increase manufacturing cost and regulatory burden.

5. Supply-chain and shortage resilience

Reliable access to pharmaceutical-grade clindamycin hydrochloride and capsule-shell materials can be a stronger commercial differentiator than a novel excipient. Dual sourcing, regional manufacturing, and validated alternate grades can reduce stock-out risk.

6. Private-label and contract manufacturing

A manufacturer with approved capsule capacity can offer the product to pharmacy chains, group purchasing organizations, hospitals, and international distributors. Margin depends heavily on contract terms and competition. The formulation should be designed for high-throughput encapsulation and multiple package configurations.

How strong is the patent estate for Cleocin hydrochloride?

The estate is weak as a barrier to standard generic entry and stronger only where a sponsor creates a new, defensible product configuration. Potentially protectable areas include:

Innovation area	Patent potential	Commercial value
Conventional lactose-based capsule	Low	Low
Lactose-free immediate-release capsule	Moderate if technically distinctive	Moderate
Non-gelatin capsule with improved stability	Moderate	Moderate
Taste-masked pediatric multiparticulate	High	High, but development-intensive
Modified-release clindamycin	Moderate to high	Uncertain because of clinical and safety complexity
Novel packaging for moisture protection	Low to moderate	Operational
Manufacturing process with yield or impurity advantage	Moderate	Primarily defensive
New indication	Potentially high	Limited by antibiotic stewardship and clinical evidence

A patent claim should rest on measurable technical performance, such as improved stability, reduced impurity formation, controlled release, improved palatability, or a defined dissolution profile. A simple substitution of one common filler for another will generally provide limited patent strength.

What patent litigation affects Cleocin hydrochloride?

There is no widely recognized current litigation profile comparable to high-value branded medicines with active composition-of-matter patents. The litigation exposure for a new generic entrant is more likely to involve routine ANDA matters, product liability, manufacturing quality, or commercial contracting than a major patent injunction.

The sponsor should still screen:

• Current Orange Book patents.
• Federal district court ANDA cases.
• Federal Circuit decisions involving the selected reference product.
• FDA approval letters and labeling changes.
• Supplier patent claims covering specialty excipients or delivery systems.

A pediatric taste-masked or modified-release product would have a materially different litigation profile from a conventional capsule.

How does Cleocin hydrochloride compare with other clindamycin products?

Product	Active form	Route	Excipient opportunity	Generic competition
Cleocin HCl capsules	Clindamycin hydrochloride	Oral	Lactose-free, non-gelatin, pediatric, supply-chain differentiation	High
Clindamycin phosphate injection	Clindamycin phosphate	Intravenous or intramuscular	Parenteral compatibility, preservative and container strategy	High
Topical clindamycin solution or gel	Clindamycin phosphate or related topical form	Topical	Vehicle, drying, skin tolerability, packaging	High
Vaginal clindamycin products	Clindamycin phosphate	Vaginal	Applicator, leakage control, local tolerability	Moderate to high
Combination products	Clindamycin with other agents	Topical or oral depending on product	Compatibility and co-delivery	Product-specific

Oral capsule reformulation is simpler than topical or vaginal delivery, but the revenue ceiling is also generally lower because the basic product is commoditized.

What generic launch scenarios exist?

Conventional low-cost launch

This strategy uses a standard capsule blend, existing API suppliers, and conventional packaging. It offers the fastest path to market but usually faces the greatest price competition.

Differentiated excipient launch

A lactose-free or non-gelatin capsule can support modest differentiation. The product remains an immediate-release generic but may gain access to selected institutional or specialty channels.

Pediatric lifecycle launch

A taste-masked liquid, sprinkle capsule, or multiparticulate product can access a less commoditized segment. Development cost, stability, clinical usability, and regulatory requirements are substantially higher.

Supply-secure institutional launch

A sponsor can compete through guaranteed availability, dual manufacturing sites, and hospital contracting. This model prioritizes operational performance over premium pricing.

What revenue exposure should investors expect?

Standalone revenue for Cleocin hydrochloride is generally not disclosed by branded manufacturers because the product is part of broader antibacterial or generic portfolios. The economic profile is therefore best assessed through:

• Annual unit demand by strength.
• Number of approved generic suppliers.
• Average selling price erosion.
• Hospital versus retail channel mix.
• API and packaging cost.
• Back-order frequency.
• Contracted volume.
• Cost of regulatory maintenance.
• Probability and timing of additional approvals.

The most attractive opportunity is not likely to be a premium conventional capsule. It is a differentiated product that solves a specific access problem, such as pediatric administration, excipient restriction, or reliable supply.

Key Takeaways

• Cleocin hydrochloride is a mature oral clindamycin capsule with limited remaining exclusivity value.
• Conventional generic entry is primarily an ANDA and manufacturing-execution opportunity.
• Lactose-free and non-gelatin formulations provide the clearest low-to-moderate differentiation options.
• Pediatric taste masking has greater patent and commercial potential but requires materially more development work.
• The major technical risks are dissolution changes, powder-flow problems, moisture sensitivity, capsule compatibility, and taste.
• Paragraph IV risk should be assessed against the current Orange Book record, but major active patent litigation is not the expected base case for a standard capsule.
• No biosimilar risk applies because clindamycin is a small-molecule antibiotic.
• Supply reliability, institutional contracting, and regulatory compliance are likely to determine commercial performance more than the choice between conventional fillers.
• A defensible patent strategy should focus on measurable formulation or manufacturing advantages rather than routine excipient substitution.

FAQs

Is Cleocin hydrochloride the same as clindamycin phosphate?

No. Both deliver clindamycin, but clindamycin hydrochloride is used primarily in oral capsules, while clindamycin phosphate is used in injectable and several topical or vaginal products.

Can a generic manufacturer change the excipients in Cleocin HCl capsules?

Yes. An ANDA may use different inactive ingredients if the formulation meets FDA requirements, remains suitable for the dosage form, and demonstrates pharmaceutical equivalence and bioequivalence.

Is a lactose-free clindamycin hydrochloride capsule commercially attractive?

It can be attractive in institutional and specialty channels, but the opportunity depends on maintaining competitive cost and proving that the formulation provides reliable manufacturing and dissolution performance.

Are clindamycin hydrochloride capsules protected by biologic exclusivity?

No. Clindamycin is a chemically synthesized small molecule and is not subject to the biosimilar approval framework.

What is the strongest lifecycle strategy for clindamycin hydrochloride?

A pediatric dosage form with effective taste masking has the greatest potential for technical differentiation. For conventional capsules, supply reliability and excipient-restriction positioning are more practical than premium pricing.

References

1. Pfizer Inc. (n.d.). Cleocin HCl (clindamycin hydrochloride) capsules: Prescribing information. U.S. Food and Drug Administration labeling repository.

2. National Library of Medicine. (n.d.). DailyMed: Clindamycin hydrochloride capsule. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.). Listing of patents and exclusivity information in the Orange Book. FDA, Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. FDA, Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (n.d.). Clindamycin: Drug safety communication and prescribing information. FDA.